| Protein Name | Glucocerebrosidase (GCase) |
|---|---|
| Gene | GBA1 |
| UniProt | P04062 |
| PDB Structures | 1OGS, 2V3D, 3KIM, 5V3E |
| Molecular Weight | 59.7 kDa (536 aa) |
| Subcellular Localization | Lysosome |
| Protein Family | Glycosylhydrolase family 30 |
| Expression | Highest in liver, spleen, brain (neurons, microglia) |
Glucocerebrosidase (GCase) is a lysosomal hydrolase encoded by the GBA1 gene that catalyzes the hydrolysis of glucosylceramide to ceramide and glucose. GBA1 mutations are the strongest genetic risk factor for Parkinson's disease and dementia with Lewy bodies, creating a crucial link between lysosomal storage disorders and neurodegenerative diseases[1].
Glucocerebrosidase is a 59.7 kDa enzyme essential for glycolipid metabolism in the lysosome. The enzyme deficiency causes Gaucher disease, the most common lysosomal storage disorder, while heterozygous mutations dramatically increase the risk of developing synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and potentially Alzheimer's disease (AD)[2].
GBA1 encodes a 536-amino acid protein:
GCase adopts a (β/α)₈ TIM barrel fold:
Key PDB structures include:
GCase catalyzes the hydrolysis of glucosylceramide (GlcCer):
Glucosylceramide + H₂O → Ceramide + Glucose
This reaction is essential for:
GBA1 mutations are the most significant genetic risk factor for idiopathic PD[3]:
| Mutation | Effect | PD Risk Increase |
|---|---|---|
| N370S | Reduced activity | 5-10x |
| L444P | Severe loss | 10-20x |
| R463C | Partial loss | 5-8x |
| E326K | Mild loss | 2-3x |
GBA1 mutations are a major risk factor for DLB[4]:
The relationship with AD is more complex:
Homozygous GBA1 mutations cause Gaucher disease:
| Type | Features | Neurodegeneration |
|---|---|---|
| Type 1 | Non-neuronopathic | None |
| Type 2 | Acute neuronopathic | Severe, early death |
| Type 3 | Chronic neuronopathic | Progressive, survi |
GCase directly binds α-synuclein:
GCase deficiency leads to:
Ceramide generation affects:
These small molecules stabilize mutant GCase[5]:
| Drug | Mechanism | Status |
|---|---|---|
| Migalastat | Active site binding | Approved for Fabry |
| Ambroxol | Chaperone activity | Phase 2 trials |
| Eliglustat | Substrate reduction | Approved for Gaucher |
Over 400 GBA1 mutations identified:
Sidransky E, et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson disease. N Engl J Med. 361(17):1651-1661. DOI:10.1056/NEJMoa0901281
Mazzulli JR, et al. (2011). Gaucher disease glucocerebrosidase deficiency and alpha-synuclein misfolding. Cell. 146(1):37-52. DOI:10.1016/j.cell.2011.06.016
Goker-Alpan O, et al. (2010). Neuropathology in Gaucher disease: evidence for neuronal storage of glucosylceramide. J Neuropathol Exp Neurol. 69(10):1028-1038. DOI:10.1097/NEN.0b013e3181f2e1e1
Clark LN, et al. (2015). Genetic association of GBA and LRRK2 mutations in Parkinson disease. JAMA Neurol. 72(11):1302-1308. DOI:10.1001/jamaneurol.2015.2091
Schapira AHV, et al. (2014). Targeting glucocerebrosidase in Parkinson disease. Nat Rev Neurol. 10(10):590-594. DOI:10.1038/nrneurol.2014.177
Do J, et al. (2019). Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 14(1):36. DOI:10.1186/s13024-019-0336-2
Aflaki E, et al. (2016). A new therapeutic approach for Parkinson disease. Ann Neurol. 80(3):358-371. DOI:10.1002/ana.24714
Liu G, et al. (2019). GBA deficiency promotes α-synuclein aggregation. Mol Neurobiol. 56(12):8366-8373. DOI:10.1007/s12035-019-01654-1
The study of Gba1 (Glucocerebrosidase) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Sidransky E, et al. (2009). Multicenter analysis of glucoceresidase mutations in Parkinson disease. N Engl J Med, 361(17):1651-1661. ↩︎
Mazzulli JR, et al. (2011). Gaucher disease glucocerebrosidase deficiency and alpha-synuclein misfolding. Cell, 146(1):37-52. ↩︎
Schapira AHV, et al. (2014). Targeting glucocerebrosidase in Parkinson disease. Nat Rev Neurol, 10(10):590-594. ↩︎
Clark LN, et al. (2015). Genetic association of GBA and LRRK2 mutations in Parkinson disease. JAMA Neurol, 72(11):1302-1308. ↩︎
Aflaki E, et al. (2016). A new therapeutic approach for Parkinson disease. Ann Neurol, 80(3):358-371. ↩︎